Physician profile
Priya Daniel
NPI 1104450899
$22,044.96
in general payments reported to CMS, 2019-2025
64 companies · $3,873 in 2025
The $3,873 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,125 · 2022: $4,920 · 2023: $3,480 · 2024: $3,648 · 2025: $3,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,809.12 |
| Education | $191.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,868.97 | 2021-2025 | |
| Emd Serono, INC. | $2,401.71 | 2021-2025 | Mavenclad |
| Biogen, INC. | $1,997.37 | 2021-2025 | Vumerity, Tysabri, Tecfidera |
| Teva Pharmaceuticals USA, INC. | $1,663.43 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lilly USA, LLC | $1,067.79 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Biohaven Pharmaceuticals, INC. | $922.49 | 2021 | |
| Neurocrine Biosciences, INC. | $852.34 | 2021-2025 | Ingrezza, Ongentys |
| Argenx US, INC. | $845.82 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $695.56 | 2024-2025 | |
| Ucb, INC. | $661.34 | 2021-2025 | Nayzilam, Fintepla, Briviact |
| E.R. Squibb & Sons, L.L.C. | $573.34 | 2021-2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $429.29 | 2021-2024 | Ultomiris |
| Horizon Therapeutics Plc | $416.92 | 2021-2023 | Uplizna |
| Janssen Pharmaceuticals, INC | $409.33 | 2021-2023 | Spravato, Ponvory |
| Eisai INC. | $376.01 | 2021-2025 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.